Sionna Therapeutics Inc 2025年季度报告

FORM10-Q_________________________ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedMarch 31, 2025 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number001-42504_________________________ SIONNA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)_________________________ (617)819-2020Registrant’s telephone number, including area code Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filingrequirements for the past 90 days.YesxNooIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit suchfiles).YesxNoo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growthcompany" in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any newor revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.o Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). YesoNoxThe number of shares of registrant’s common stock outstanding as of May 1, 2025 was44,124,394 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (the “Quarterly Report”) contains forward-looking statements about us andour industry that involve substantial risks and uncertainties, and which are made pursuant to the safe harbor provisions ofSection 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities ExchangeAct of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts contained in thisQuarterly Report, including statements regarding our future results of operations and financial position, business strategy,product candidates, preclinical studies and clinical trials, results of preclinical studies and clinical trials, research anddevelopment costs, regulatory approvals, commercial strategy, timing and likelihood of success, as well as plans andobjectives of management for future operations, are forward-looking statements. Although we believe that theexpectations reflected in these forward-looking statements are reasonable, these statements involve known and unknownrisks, uncertainties and other important factors that are in some cases beyond our control and may cause our actualresults, performance or achievements to be materially different from any future results, performance or achievementsexpressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “would,”“expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential” or “continue” orthe negative of these terms or other similar expressions. Forward-looking statements contained in this Quarterly Reportinclude, but are not limited to, statements about: •the initiation, timing, progress and results of our research and development programs, preclinical studies andclinical trials;•the ability of clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results,and the ability of our preclinical studies to predict later clinical trial results;•the timing, scope and likelihood of regulatory filings and approvals of our product candidates;•the implementation of our business model, and strategic plans for our business, programs, and current and futureproduct candidates;•our ability to obtain additional cash and the sufficiency of our existing cash, cash equivalents and investments inmarketable securities to fund our future operating expenses and capital expenditure requirements;•the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additionalfinancing;•the size and growth potential of the markets for our product candidates, and our ability to serve those markets; ourpotential and ability to successfully manufacture and supply our current and future product candidates for clinicaltrials and for commercial use,